导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.32% | 1676/4773 |
| 近一周 | -2.49% | 2337/5462 |
| 近一月 | -4.92% | 2867/5421 |
| 近一季 | -9.59% | 3275/5209 |
| 近半年 | -6.83% | 3145/4920 |
| 近一年 | 7.30% | 1329/4366 |
| 近两年 | 71.85% | 944/2954 |
| 近三年 | 38.04% | 774/2253 |
| 成立以来 | 91.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.05% 1080/4961 |
18.72% 1350/5312 |
- - |
- - |
| 2025 | 31.83% 1216/4813 |
2.76% 1270/3635 |
2.14% 1824/4076 |
24.26% 1485/4524 |
1.07% 1554/4813 |
| 2024 | 7.31% 1672/3463 |
-2.69% 1408/2808 |
-4.95% 1599/3014 |
15.54% 1689/3129 |
0.41% 1215/3463 |
| 2023 | -4.40% 674/2656 |
7.69% 535/2280 |
-3.42% 793/2385 |
-3.79% 988/2515 |
-4.47% 1048/2655 |
| 2022 | -16.47% 483/2207 |
-12.94% 669/1919 |
3.32% 1170/2016 |
-9.67% 294/2113 |
2.79% 833/2208 |
| 2021 | 22.03% 156/1822 |
-0.41% 362/1255 |
11.43% 376/1330 |
5.79% 256/1466 |
3.94% 381/1822 |
| 2020 | - - |
- - |
18.31% 342/1067 |
11.45% 446/1164 |
4.11% 867/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证500ETF联接A VS. 长安沪深300非周期A(740101) |